Acute Migraine Drugs Market Focuses on Growth

Acute Migraine Drugs Market Focuses on Growth Factors, Technological Innovation, Growth and Forecast 2023 to 2032

The Brainy Insights launched a study titled
Acute Migraine Drugs Market Size by Route of Administration (Injection, Oral,
& Others), Treatment (Pain Relieving & Preventive), End-User, Regions,
Global Industry Analysis, Share, Growth, Trends, and Forecast 2022 to 2030

The global acute
migraine drugs market is expected to grow from 4.3 billion in 2021 to USD 9.26
billion by 2030, at a CAGR of 8.90% during the forecast period 2022-2030. Significant
development drivers of the migraine drug market contain the high prescription
of gepants, calcitonin gene-related peptide (CGRP) antagonists, and monoclonal
antibodies (mAbs) as preventative migraine therapy. These medication types will
claim a significant patient share across 7MM during the projection time. The
number of twelve-month total general cases of migraine is anticipated to rise
during the projection time, which will expand the diagnosed and treated
population and push sales.

Request sample copy of this
report at: https://www.thebrainyinsights.com/report/acute-migraine-drugs-market-12885

The oral segment dominated the market,
accounting for around 1.50 billion global revenue in 2021.

The route of
administration segment is divided into injection, oral, and others. The oral
segment dominated the market, accounting for around 1.50 billion global revenue
in 2021. Oral drugs are convenient to take and easily dissolve in the blood; it
doesn't require any particular observation while consuming.

The preventive segment dominated the
market, accounting for around 2.40 billion global revenue in 2021.

The treatment
segment is divided into pain relieving, and preventive. The preventive segment
dominated the market, accounting for around 2.40 billion global revenue in
2021. In the preventive market, recent research concentrates on utilizing new
mechanisms of action, like ligand inhibition, antagonism, CGRP-based receptor,
nitrous oxide inhibition, and corticotrophin receptor. Acceptance of CGRP
monoclonal antibodies is one of the critical growth factors.

The hospital pharmacies segment dominated
the market, accounting for around 1.59 billion global revenue in 2021.

The end-user
segment is divided into online pharmacies, retail pharmacies, and hospital
pharmacies. The hospital pharmacies segment dominated the market, accounting
for around 1.59 billion global revenue in 2021. A hospital
pharmacy is a unit within a hospital that organizes,
stocks, compounds, and dispenses patient medications. Hospital pharmacies
usually store a more extensive range of drugs, including more specialized and
investigational medicines.

Access Full Reports : https://www.thebrainyinsights.com/enquiry/sample-request/12885

Regional Segmentation Analysis:

The market is
analyzed based on five regions: North America, Europe, Asia Pacific, South
America, and the Middle East and Africa. North
America is expected to be the largest market during the forecast period. The
majority of migraine problem is high in the Americas. Around 11% of the United
States people, including 17% of women, 5% of men, and 9% of youths, were
dealing with migraines in the US region. However, the healthcare infrastructure
in the US is also well maintained, contributing to market development.
Similarly, prominent pharmaceutical firms like Alder Biopharmaceuticals, Inc.
and Pfizer Inc. are headquartered in the United States, favourably contributing
to the development of the migraine drugs market in the region.

Competitive Analysis:

The
market’s major players include Teva Pharmaceutical, Pfizer Inc., Novartis AG, Merck
& Co., Johnson and Johnson, Hoffmann-La Roche Ltd., Eli Lilly and Company,
AstraZeneca, Amgen, among others.